This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix net loss increases in second quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix reported a second quarter net loss of $24.5 million, or $0.57 per share, compared with a net loss of $13.8 million, or $0.37 per share, for the same period in 2018, according to a press release.

Revenues were $600,000, the same as in 2018.

Research and development expenses were $9.4 million compared with $8.7 million in the comparable period in 2018. General and administrative expenses were $5.1 million compared with $4.4 million in 2018.

Selling and marketing expenses were $7.2 million compared with $900,000 in the second quarter of 2018. The increase was attributed to preparation for the commercial launch of Dextenza (dexamethasone ophthalmic insert), which treats ocular inflammation and pain after ophthalmic surgery.

Ocular Therapeutix had $61.8 million in cash and cash equivalents as of June 30.